Global Progenitor Cell-Based Market Quantitative Market Analysis, Current and Fu

Posted by Rashi Pande on November 28th, 2019

Market Analysis: Global Progenitor Cell-Based Market

Global progenitor cell-based market is estimated to register a substantial CAGR in the forecast period of 2019 to 2026. The imminent market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026. The growth of the market can be attributed to the rising geriatric population.

Key Market Competitors:

Some of the major companies functioning in global progenitor cell-based market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co., Inc., Abbott, Vericel, Novartis AG, Alcon, GlaxoSmithKline plc, BAXTER INTERNATIONAL INC, Boehringer Ingelheim International GmbH, Amgen Inc., Bristol-Myers Squibb Company, Nuvasive, Inc., Organogenesis, Inc., Nu-Tech International,  MiMedx, Stability Biologic., Takara Bio Inc., Caladrius, Biosciences, Inc., U.S. Stem Cell, Inc., Cesca Therapeutics and Osiris Therapeutics, Inc among others

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-progenitor-cell-based-market

Market Definition: Global Progenitor Cell-Based Market

Progenitor cell are the kind of stem cell which are located in bone marrow and also called as hematopoietic. These cells give rise to the different cell lines. The progenitor cells can divide and stem cells can replicate indefinitely. Progenitor cells are used in various neurological disorders such as Parkinson disease and Huntington disease.

Prevalence of Parkinson’s disease (PD) increases with increasing age but an estimated four percent of people with Parkinson’s disease are diagnosed before age 50, more than 10 million people worldwide are living with Parkinson’s disease, and other neurological diseases.

Market Drivers

• Rising of advanced genome-cell based techniques is driving the growth of the market
• Investment in research and development activities along with government funding in   regenerative medicine will propel the market growth
• Increasing number of clinical trials based on cell-based therapy is also fueling the market to grow in the forecast period
• Development in cell banking infrastructure is boosting the market growth

Market Restraints

• Unclear regulatory guidelines for product development is hampering the growth of the market
• Less  availability of skilled professional may also hinder the market in the forecast period
• Ethical concern in animal trial can hamper the market growth

Segmentation: Global Progenitor Cell-Based Market

By Type

• Allogeneic Stem Cell
  • Musculoskeletal Disorders
  • Wounds and Injuries
  • Surgeries
  • Acute Graft-Versus-Host Disease (AGVHD)
  • Others
• Autologous
  • Wounds and Injuries
  • Cardiovascular Diseases
  • Gastrointestinal Diseases
  • Others

By Therapeutic Application

• Musculoskeletal Disorders
• Wound and Injuries
• Neurology
• Cardiovascular Diseases (CVD)
• Gastrointestinal Diseases
• Surgeries
• Others

By Cell Source

• Adipose Tissue-Derived Mesenchymal Stem Cells
• Bone Marrow-Derived Mesenchymal Stem Cells
• By Embryo/Cord Blood Stem Cells
• Others

By End User

• Laboratory
• Hospitals
• Research Institute

By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• South America
  • Brazil
  • Rest of South America
• Europe
  • Germany
  • Italy
  • U.K.
  • France
  • Spain
  • Netherlands
  • Belgium
  • Switzerland
  • Turkey
  • Russia
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Singapore
  • Thailand
  • Philippines
  • Rest of Asia-Pacific
• Middle East and Africa
  • South Africa
  • Rest of Middle East & Africa

Key Developments in the Market:

• In April 2019, Boehringer Ingelheim International GmbH, announced the launch of Arti Cell, a first ever registered stem cell-based veterinary medicine. This is ground breaking approved therapy which will use to reduce mild to moderate recurrent lameness related with non-septic joint inflammation in horses. With this launch, the company will enhance its product portfolio in the market
• In January 2019, Japan government organization approved stem-cell treatment for spinal-cord injuries. This stem cell treatment is used to contract muscles and sense touch of the body. This approval will provide direction to the new era of healthcare and will create unprecedented revolution of science and medicine